Literature DB >> 449682

Hyperglucagonemia in liver cirrhosis with portal-systemic venous anastomoses: responses of plasma glucagon and gastric inhibitory polypeptide to oral or intravenous glucose in cirrhotics with normal or elevated fasting plasma glucose levels.

T J McDonald, J Dupre, Y Caussignac, J Radziuk, S Van Vliet.   

Abstract

Plasma immunoreactive glucagon (IRG) was examined in volunteers with biopsy-proven cirrhosis of the liver after recovery from surgical portal--caval anastomosis. A wide range of increased total plasma IRG concentrations was found after overnight fast in groups of cirrhotic subjects with and without fasting hyperglycemia. Gel filtration chromatography of plasma showed a major component in the 3500-mol wt fraction in all cases so studied. Administration of glucose i.v. caused rapid suppression of total plasma IRG in normoglycemic and non-insulin-dependent hyperglycemic cirrhotic subjects. After administration of oral glucose, total plasma IRG was suppressed rapidly in normoglycemic cirrhotic subjects, while non-insulin-dependent hyperglycemic cirrhotic subjects exhibited delayed but prolonged suppression. Chromatography of selected plasma with glucose-suppressed total IRG showed a major decrease in the 3500-mol wt component in every case. Exaggerated increments of plasma gastric inhibitory polypeptide were demonstrable in both groups of cirrhotic individuals after administration of oral glucose, and it is speculated that this peptide may contribute to stimulation of glucagon secretion in liver disease associated with insulin deficiency.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 449682     DOI: 10.1016/0026-0495(79)90099-4

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  5 in total

1.  Absence of hepatic extraction of gastric inhibitory polypeptide in conscious dogs.

Authors:  Z Chap; T M O'Dorisio; S Cataland; J B Field
Journal:  Dig Dis Sci       Date:  1987-03       Impact factor: 3.199

2.  Interaction of fat-stimulated gastric inhibitory polypeptide on pancreatic alpha and beta cell function.

Authors:  C A Verdonk; R A Rizza; R L Nelson; V L Go; J E Gerich; F J Service
Journal:  J Clin Invest       Date:  1980-05       Impact factor: 14.808

3.  Endocrine aspects of liver disease.

Authors:  R G Long
Journal:  Br Med J       Date:  1980-01-26

4.  C-peptide in non-alcoholic cirrhosis and hepatocellular carcinoma.

Authors:  K K Pun; P W Ho; R T Yeung
Journal:  J Endocrinol Invest       Date:  1988-05       Impact factor: 4.256

5.  Adrenergic modulation of gastric inhibitory polypeptide secretion in man.

Authors:  M Salera; R Ebert; P Giacomoni; L Pironi; S Venturi; R Corinaldesi; M Miglioli; L Barbara
Journal:  Dig Dis Sci       Date:  1982-09       Impact factor: 3.199

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.